Neuroscience
Top 10 Phase III Failures of 2010
From
FierceBiotech, an interesting report:
Full article: Top 10 Phase III Failures of 2010
-
Alzheimer: Clinical Trials Day At The Aaic2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015. - Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years - Biomarker Results from Phase 3 Gantenerumab (Roche) Trial - New Data from Aducanumab (Biogen) Phase 1b...
-
Alzheimer's Disease: Negative Bapineuzumab Findings In Phase Iii Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release. From FierceBiotech: UPDATED: Pfizer, J&J...
-
Business World: Gsk's Rare Diseases R&d Unit
From FierceBiotech: GSK launches new specialist unit to research and develop medicines for rare diseases Issued: Thursday 4 February 2010, London UK Read the full article...
-
Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
-
Acadia's Pimavanserin And Parkinson Disease Psychosis
FierceBiotech reported today about a failed Phase III trial of Acadia's Pimavanserin in a study of Parkinson's Disease Psychosis (sometimes abbreviated as "PDP"): ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in...
Neuroscience